Actinomycin D (CAS 50-76-0)

Actinomycin D is a metabolite isolated from Streptomyces parvulus. Actinomycin D binds to the GpC steps of DNA. Actinomycin D acts as an antibiotic, and is more effective against gram positive bacteria than gram negative bacteria. Actinomycin D can induce apoptosis in several cell lines such as lung and prostate cancer lines, and human blood lymphocytes, among others. In studies, it has been observed that Actinomycin D elevates p53 expression, leading to the increase of PUMAα/β (the p53 upregulated modulator of apoptosis protein; PUMA). Actinomycin D can also induce tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced caspase-dependent and -independent apoptosis.

References:

1. Actinomycin D induces apoptosis and inhibits growth of pancreatic cancer cells.  |  Kleeff, J., et al. 2000. Int J Cancer. 86: 399-407. PMID: 10760829
2. Effect of actinomycin D on cellular nucleic acid synthesis and virus production.  |  REICH, E., et al. 1961. Science. 134: 556-7. PMID: 13740412
3. THE EFFECTS OF ACTINOMYCIN D ON GROWTH OF ROUS SARCOMA VIRUS IN VITRO.  |  TEMIN, HM. 1963. Virology. 20: 577-82. PMID: 14059825
4. Actinomycin D upregulates proapoptotic protein Puma and downregulates Bcl-2 mRNA in normal peripheral blood lymphocytes.  |  Kalousek, I., et al. 2007. Anticancer Drugs. 18: 763-72. PMID: 17581298
5. Actinomycin D enhances TRAIL-induced caspase-dependent and -independent apoptosis in SH-SY5Y neuroblastoma cells.  |  Wang, MJ., et al. 2007. Neurosci Res. 59: 40-6. PMID: 17707539
6. Actinomycin D and 7-aminoactinomycin D binding to single-stranded DNA.  |  Wadkins, RM. and Jovin, TM. 1991. Biochemistry. 30: 9469-78. PMID: 1892847
7. Specific activation of the p53 pathway by low dose actinomycin D: a new route to p53 based cyclotherapy.  |  Choong, ML., et al. 2009. Cell Cycle. 8: 2810-8. PMID: 19657224
8. Actinomycin D decreases Mcl-1 expression and acts synergistically with ABT-737 against small cell lung cancer cell lines.  |  Xu, H. and Krystal, GW. 2010. Clin Cancer Res. 16: 4392-400. PMID: 20732961
9. Effects of morpholinyl doxorubicins, doxorubicin, and actinomycin D on mammalian DNA topoisomerases I and II.  |  Wassermann, K., et al. 1990. Mol Pharmacol. 38: 38-45. PMID: 2164630
10. Stabilization of type I topoisomerase-DNA covalent complexes by actinomycin D.  |  Trask, DK. and Muller, MT. 1988. Proc Natl Acad Sci U S A. 85: 1417-21. PMID: 2830618
11. Isolation, characterization, anti-MRSA evaluation, and in-silico multi-target anti-microbial validations of actinomycin X2 and actinomycin D produced by novel Streptomyces smyrnaeus UKAQ_23.  |  Qureshi, KA., et al. 2021. Sci Rep. 11: 14539. PMID: 34267232
12. Cellular resistance to actinomycin D in Chinese hamster cells in vitro: cross-resistance, radioautographic, and cytogenetic studies.  |  Biedler, JL. and Riehm, H. 1970. Cancer Res. 30: 1174-84. PMID: 5533992
13. Inhibition of apoptosis by antioxidants in the human HL-60 leukemia cell line.  |  Verhaegen, S., et al. 1995. Biochem Pharmacol. 50: 1021-9. PMID: 7575657
14. Influence of DNA base sequence on the binding energetics of actinomycin D.  |  Bailey, SA., et al. 1993. Biochemistry. 32: 5881-7. PMID: 8504108